Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Multiple sclerosis and neuroimmunology

Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging.

Rosa Cortese; Ferran Prados Carrasco; Carmen Tur; Alessia Bianchi; Wallace Brownlee; Floriana De Angelis; Isabel De La Paz; Francesco Grussu; Lukas Haider; Anu Jacob; Baris Kanber; Lise Magnollay; Richard S Nicholas; Anand Trip; Marios Yiannakas; Ahmed T Toosy; Yael Hacohen; Frederik Barkhof; Olga Ciccarelli

Originally published in Neurology · 2022-10-03

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Background and objectives Relapsing-remitting multiple sclerosis (RRMS), aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) may have overlapping clinical features. There is an unmet need for imaging markers that differentiate between them when serologic testing is unavailable or ambiguous. We assessed whether imaging characteristics typical of MS discriminate RRMS from AQP4-NMOSD and MOGAD, alone and in combination. Methods Adult, nonacute patients with RRMS, APQ4-NMOSD, and MOGAD and healthy controls were prospectively recruited at the National Hospital for Neurology and Neurosurgery (London, United Kingdom) and the Walton Centre (Liverpool, United Kingdom) between 2014 and 2019. They underwent conventional and advanced brain, cord, and optic nerve MRI and optical coherence tomography (OCT). Results A total of 91 consecutive patients (31 RRMS, 30 APQ4-NMOSD, and 30 MOGAD) and 34 healthy controls were recruited.

Discussion

In this work, we identified differences in brain, cervical cord, and optic nerve involvement between nonacute RRMS, AQP4-NMOSD, and MOGAD patient groups using different imaging modalities.

Editorial reading guide

  • Which patient population and reference standard did the authors use?
  • Was the finding validated in a separate cohort, and how might patient selection affect it?